New insights into uremia-induced alterations in metabolic pathways

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 6, 2011, Pages 593-598

  Rhee, Eugene P ^a,b   Thadhani, Ravi ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

ESRD; metabolite profiling; metabolomics; uremia; uremic toxin

Indexed keywords

AST 120; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDICAN; TRIACYLGLYCEROL; TRIMETHYLAMINE OXIDE; TRYPTOPHAN; UREMIC TOXIN;

DISEASE ASSOCIATION; DYSLIPIDEMIA; GENE OVEREXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLIC DISORDER; METABOLITE; METABOLOMICS; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; TRYPTOPHAN METABOLISM; UREMIA;

DYSLIPIDEMIAS; HUMANS; KIDNEY FAILURE, CHRONIC; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; PHOSPHATIDYLCHOLINES; TRIGLYCERIDES; TRYPTOPHAN; UREMIA;

EID: 80054773913     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32834b8a1d     Document Type: Review

References (39)

1. Meyer TW, Hostetter TH. Uremia. N Engl J Med 2007; 357:1316-1325.
2. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63:1934-1943. (Pubitemid 36513344)
3. Lewis GD, Asnani A, Gerszten RE. Application of metabolomics to cardiovascular biomarkerand pathway discovery. J Am Coll Cardiol 2008; 52:117-123. (Pubitemid 351885452)
4. Bain JR, Stevens RD, Wenner BR, et al. Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 2009; 58:2429-2443.
5. Psychogios N, Hau DD, Peng J, et al. The human serum metabolome. PLoS One 2011; 6:e16957.
6. Niwa T. Recent progress in the analysis of uremic toxins by mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:2600-2606.
7. Niwa T. Update of uremic toxin research by mass spectrometry. Mass Spectrom Rev 2011; 30:510-521.
8. Rhee EP, Souza A, Farrell L, et al. Metabolite profiling identifies markers of uremia. J Am Soc Nephrol 2010; 21:1041-1051.
9. Koenig P, Nagl C, Neurauter G, et al. Enhanced degradation of tryptophan in patients on hemodialysis. Clin Nephrol 2010; 74:465-470.
10. Schefold JC, Zeden JP, Fotopoulou C, et al. Increased indoleamine 2, 3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant 2009; 24:1901-1908.
11. Toyohara T, Akiyama Y, Suzuki T, et al. Metabolomic profiling of uremic solutes in CKD patients. Hypertens Res 2010; 33:944-952.
12. Niwa T. Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr 2010; 20 (5 Suppl):S2-S6.
13. Sirich T, Meyer TW. Indoxyl sulfate: long suspected but not yet proven guilty. Clin J Am Soc Nephrol 2011; 6:3-4.
14. Kikuchi K, Itoh Y, Tateoka R, et al. Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:1662-1668.
15. Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011; 6:30-39.
16. Ito S, Osaka M, Higuchi Y, et al. Indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of E-selectin. J Biol Chem 2010; 285:38869-38875.
17. Masai N, Tatebe J, Yoshino G, Morita T. Indoxyl sulfate stimulates monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells by inducing oxidative stress through activation of the NADPH oxidase-nuclear factor-kappaB pathway. Circ J 2010; 74:2216-2224.
18. Lekawanvijit S, Adrahtas A, Kelly DJ, et al. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010; 31:1771-1779.
19. Shimizu H, Bolati D, Adijiang A, et al. Senescence and dysfunction of proximal tubular cells are associated with activated p53 expression by indoxyl sulfate. Am J Physiol Cell Physiol 2010; 299:C1110-C1117.
20. Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4:1551-1558.
21. Wang J, Simonavicius N, Wu X, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 2006; 281:22021-22028. (Pubitemid 44181906)
22. Barth MC, Ahluwalia N, Anderson TJ, et al. Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem 2009; 284:19189-19195.
23. Wang Y, Liu H, McKenzie G, et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med 2010; 16:279-285.
24. Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 2009; 204:309-314.
25. Pawlak K, Mysliwiec M, Pawlak D. Kynurenine pathway: a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients. Adv Med Sci 2010; 55:196-203.
26. Pawlak K, Mysliwiec M, Pawlak D. Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients. Thromb Res 2010; 125:e40-e45.
27. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1395-1407.
28. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238-248. (Pubitemid 41058323)
29. Karumanchi SA, Thadhani R. Kidney complications: why don't statins always work? Nat Med 2010; 16:38-40.
30. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcho-line promotes cardiovascular disease. Nature 2011; 472:57-63.
31. Schepers E, Glorieux G, Vanholder R. The gut: the forgotten organ in uremia? Blood Purif 2010; 29:130-136.
32. Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 2009; 106:3698-3703.
33. Rhee EP, Cheng S, Larson MG, et al. Lipid profiling identifies atriacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 2011; 121:1402-1411.
34. Sim KG, Hammond J, Wilcken B. Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders. Clin Chim Acta 2002; 323 (1-2):37-58. (Pubitemid 34804794)
35. Sato E, Kohno M, Yamamoto M, et al. Metabolomic analysis of human plasma from haemodialysis patients. Eur J Clin Invest 2011; 41:241-255.
36. Godfrey AR, Williams CM, Dudley E, et al. Investigation of uremic analytes in hemodialysate and their structural elucidation from accurate mass maps generated by a multidimensional liquid chromatography/mass spectrometry approach. Rapid Commun Mass Spectrom 2009; 23:3194-3204.
37. Kikuchi K, Itoh Y, Tateoka R, et al. Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:2997-3002.
38. Toyohara T, Suzuki T, Morimoto R, et al. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol 2009; 20:2546-2555.
39. Wikoff WR, Nagle MA, Kouznetsova VL, et al. Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J Proteome Res 2011; 10:2842-2851.